FDA clears ADAC's coincidence detection
Nuclear medicine vendor ADAC Laboratories of Milpitas, CA, gota helping hand from the Food and Drug Administration at this year'sRadiological Society of North America meeting. The agency clearedADAC's 510(k) application for its molecular coincidence
Nuclear medicine vendor ADAC Laboratories of Milpitas, CA, gota helping hand from the Food and Drug Administration at this year'sRadiological Society of North America meeting. The agency clearedADAC's 510(k) application for its molecular coincidence detection(MCD) technique just days before the Chicago conference.
MCD enables nuclear medicine physicians to image high-energyPET radioisotopes like fluorodeoxyglucose without the use of heavycollimators (SCAN 6/21/95). ADAC is bullish on the technology,which it believes will lead to increased applications in nuclearmedicine. The company is sponsoring a multicenter trial startingearly next year to validate the clinical utility of MCD, accordingto Ian Farmer, vice president of marketing.
Several other nuclear medicine vendors are developing coincidencedetection techniques, but ADAC believes it has an 18 to 24-monthlead on its competitors in bringing a product to market, Farmersaid.
In other ADAC news, the company last month acquired JD TechnicalServices of Washington, MO, a gamma camera service and refurbishingfirm. The $1.7 million acquisition enables ADAC to refurbish andsell cameras made by other vendors. The company will also be thecornerstone of ADAC's new multivendor gamma camera service program,according to Farmer (see story, page 5).
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
